The goal of this clinical trial is to learn more about the safety and efficacy of an investigational drug called Alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma.
This is an upcoming trial that has not yet started accepting patients.
This trial is seeking approximately 466 patients who will be randomly assigned into one of two different groups (or arms). This trial is open-label, which means that both researchers and participants will know which arms they are placed in, and which medications and doses they will be receiving. Study participants may continue to receive study medications unless their myeloma gets worse, or they experience serious side effects.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Phase 3
Enrollment: 466 patients (estimated)
View MoreView all clinical trial locations sorted by state.
Birmingham, AL
Iowa City, IA
Bethesda, MD
Southfield, MI
Hackensack, NJ
New York, NY
Rochester, NY
Chapel Hill, NC
Cincinnati, OH
Cleveland, OH
Columbus, OH
Seattle, WA
Madison, WI
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby LocationsYou can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message
Learn more about how we work with trial sponsors